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The origins of my ultimate career focus in neonatal
neurology began in the early 1960s with my exposure to the
development of the central nervous system by teaching
from such ﬁgures as Richard Sidman, Pasko Rakic, and
Raymond Adams at Harvard Medical School. The neuro-
anatomy and neuropathology of the developing central
nervous system fascinated me, and my interactions in
medical school with these great ﬁgures profoundly inﬂu-
enced me. When, in 1963-1964, I reached the “clinical
years”, as they were termed in medical school in those days,
I was enormously stimulated by Philip Dodge and became
committed to a career in child neurology. After training in
pediatric neurology at the Massachusetts General Hospital,
especially under the inﬂuence of such ﬁgures in neurology
as Raymond Adams and C. Miller Fisher, and in neuropa-
thology, E.P. Richardson, I reunited with Philip Dodge at
Washington University in St. Louis, where he had been
recruited as Chair of Pediatrics.Neonatal neurology
Wisdom of Phil Dodge
Shortly aftermy arrival atWashington University in 1971,
as I attempted to determine what subspecialty area in child
neurology I would pursue, I had a conversation with Phil
Dodge that I remember to this day. He earlier had recog-
nized the great importance of the advent of neonatal
intensive care in the 1960s, the likely impact of this area in
pediatrics in the near future, and the probable emergence of
neonatal neurological disease as a major complication. HeThis is an open access article under the CC BY-NC-ND license (http://
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long-standing interest in the developing nervous system.
He suggested, in his characteristically gentle and under-
stated way, that neonatal neurology could be an important
ﬁeld to be developed and that this ﬁeld would ﬁt well with
my neurological interests. My initial reaction to Phil’s sug-
gestion, in retrospect, reﬂected my naiveté in the face of his
wisdom. I protested that neonatology would not be inter-
esting because it would limit the personal interactions with
my young patients, interactions I treasured. However, after
considerable thought, I realized the wisdom of Phil’s advice
and decided to explore an emphasis on neonatal neurology.
My initial explorations into neonatal neurology as a po-
tential ﬁeld of speciﬁc interest were stimulating. I was
fascinated by the clinical descriptions of the development of
newborns and young infants by such ﬁgures as Prechtl,
Saint-Anne Dargassies, Amiel-Tison, Peiper, Dubowitz
(Lilly), and Brazelton. Perhaps most of all, I was greatly
stimulated by the classical early neuropathologic writings
by Banker, Larroche, Rorke, Friede, and Yakovlev. Yet, in
spite of this rich literature, a clear clinicopathologic
approach to the newborn, systematic, detailed, and
comprehensive, was lacking. Developing such an approach
struck me as the key initial challenge. Thus I set about to
apply the child neurologist’s perspective of clinical phe-
nomena and neuropathology to the study of the newborn in
health and diverse diseases.
Early years
My early years in neonatal neurology were more than
challenging. I felt that if I were to fully understand the crit-
ically ill newborn, I would need to learn neonatology. Thus, I
studied the ﬁeld intensely and perhaps most importantly,
embarked on regular rotations as an attending physician in
the neonatal intensive care unit, caring for the pulmonary
and other systemic issues so prominent in these sick infants,
as well, of course, for the neurological complications. Fortu-
nately, for both the infants and me, neonatologists worked
over my shoulder to ensure that lungs, heart, and otherreserved.
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care became more complex later in the 1970s, I ceased my
work as a neonatology attending, but never lost the aware-
ness of the importance of the infant’s systemic complications
in the setting of neonatal neurological disease.
The advances in neonatal intensive care in the 1970s
related especially to advances in respiratory care. Thus, the
prolonged use of positive pressure ventilators in the 1960s
gave way to such measures as continuous positive airway
pressure, intermittent mandatory ventilation, and other im-
provements. Marked increases in survival rates in smaller
and smaller preterm infants ensued pari passu. Nonetheless,
such improvements in survival rates were accompanied by a
wide recognition of neonatal neurological disorders. Such
disorders as severe intraventricular hemorrhage (IVH) and its
complications were recognized initially as especially promi-
nent pathologies. My efforts during those years focused on
the relations of deranged cerebral hemodynamics to
neonatal neuropathology, especially IVH and its complica-
tions, as well as ischemic lesions, and the means to prevent
those derangements. My ﬁrst fellows (Jeff Perlman, a
neonatal fellow who now is Chief of Neonatology at Cornell
and a leader in neonatal neurology and Alan Hill, a child
neurology fellow who subsequently contributed importantly
to the ﬁeld for decades while Chief of Child Neurology in
Vancouver) were remarkably productive during this period.
We also were greatly inspired by the work on cerebral blood
ﬂow by the group in Copenhagen (Hans Lou and later among
others, Gorm Greisen). Moreover, the imaging (computed
tomography [CT], ultrasonography) and related studies by
many workers, especially LuAnn Papile, Laura Ment, Carol
Rumack, and Karen Pape, greatly embellished the ﬁeld. The
pathologic studies by Takashima, Wigglesworth, and Gilles
provided critical structural context.
During the 1970s, a particular focus for me also included
term infants with perinatal asphyxia and hypoxic-ischemic
encephalopathy. Another child neurology fellow, the late
Joseph Pasternak, worked with me as we began to delineate
speciﬁc subtypes of hypoxic-ischemic disease. We were
greatly stimulated by the experimental studies of Myers,
Brann, and Vannucci, among others.
A critical personal milestone
A major milestone in my career, like so many other
milestones in my early years, developed after another con-
versation with Phil Dodge in the mid-1970s. I had begun to
sense that a comprehensive source of information on the
neurology of the newborn was needed, i.e., a book. When I
discussed preparation of a book in this ﬂedgling ﬁeld, he
cringed and advisedme not to do it. He felt thatmy academic
career, especially my laboratory research, a critical compo-
nent of my career, would suffer. This advice was the only
counsel from Phil that I did not heed. I wanted to take on this
challenge, and I was determined to pursue the endeavor as a
single author. Thus I began the preparation of the ﬁrst edition
of Neurology of the Newborn in the late 1970s. After several
years of research and writing, this edition was published in
1981. There followed four subsequent editions, the last of
which, the ﬁfth edition, was published in 2008. After the ﬁrst
edition, the ﬁeld of neonatal neurology grew explosively (see
in the following), and as a consequence, the preparation ofeach edition was progressively more difﬁcult. Indeed from
the ﬁrst book with 225 ﬁgures, 273 tables, and 3300 refer-
ences, the volumes grew progressively, and in the ﬁfth edi-
tion, 663 ﬁgures, 548 tables, and approximately 13,000
references were included. In spite of the increasingly painful
gestations, the book remained for me a labor of love.
Explosion in neonatal neurology
The explosion in neonatal neurology as a discipline
began in the 1980s and has continued to the present day. I
recall in the late 1970s to early 1980s presenting our work in
a few abstracts to the small Child Neurology section at the
annual meeting of the Pediatric Academic Societies (then,
Society for Pediatric Research). There were essentially no
presentations on neonatal neurology in the many sub-
sections of the huge neonatology sessions at those meet-
ings. Later, in the 1980s and into the 1990s, a dramatic
increase in presentations related to neonatal neurology
became apparent, such that several hundred such abstracts
were accepted, and most interestingly, virtually all were
chosen for neonatology subsections. Perhaps most sur-
prisingly, the large majority of such presentations were by
neonatologists. This trend has continued, such that in the
present day the work on neonatal neurology presented at
the Pediatric Academic Societies meeting is predominantly
authored by neonatologists. The interest in this ﬁeld within
neonatology now rivals the traditional degree of emphasis
on respiratory disease in that specialty. Indeed, current
leaders in neonatal neurology include such distinguished
ﬁgures in neonatology as David Edwards, Frances Cowan,
Mary Rutherford in the United Kingdom, Linda de Vries in
the Netherlands, Petra Huppi in Switzerland, and, of course,
Jeff Perlman in the United States, among many others.
Recent years
Over the last 20-25years,with theadvent in the late 1980s
of commercial surfactant use and slightly later, antenatal
steroid use, severity of respiratory distress syndrome
declined and, in tandem, so did severe IVH and its compli-
cations. My attention turned more to the nature of the
principalbrainabnormality inpreterminfants andultimately
thecombinationofwhite andgraymatterdisturbances I have
termed the “encephalopathy of prematurity.” Around the
turn of the century, work with Petra Huppi (now Chief of
ChildDevelopment inGeneva) andTerrie Inder (nowChair of
Pediatric Newborn Medicine at Harvard) used advanced
magnetic resonance techniques to deﬁne the macrostruc-
tural and microstructural features of this abnormality. Many
investigators also have contributed importantly to these as-
pects of neonatal neurology. Some prominent ﬁgures are Jim
Barkovich (University of California at San Francisco [UCSF]),
SteveMiller (Toronto, followingUCSF, andVancouver), David
Edwards (United Kingdom), Jeff Neil (Harvard, following
Washington University in St Louis), Robert McKinstry (St.
Louis), Linda de Vries (The Netherlands), and James
Boardman (United Kingdom).
Meanwhile, my work in the laboratory focused inten-
sively on the mechanisms of injury in cerebral white matter
in the preterm infant and the interventions to prevent that
injury. An especially productive fellow (among many other
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leader of his own excellent research program in Portland,
Oregon. My colleagues in this mechanistic work have been
Paul Rosenberg (Harvard) and Frances Jensen (now Chair of
Neurology at the University of Pennsylvania). This work was
funded for many years by the National Institutes of Health
as a Program Project. We have been stimulated by such
ﬁgures as Donna Ferriero (UCSF), David Rowitch (UCSF),
Pierre Gressens (Paris and London), and Henrik Hagberg
(Sweden and London).
In the past 15-20 years, I have also focused especially on
the anatomic aspects of the brain abnormality in preterm
infants, with my great friend and inspiring colleague,
Dr. Hannah Kinney. The results of advanced techniques to
study human brain, i.e., immunocytochemistry, computer-
based quantitation, Western blotting, in situ hybridization,
and other modern cellular and molecular methods (see
later), have convinced us that a return to the study of
neonatal anatomy and pathology in human brain is essen-
tial for future progress in neonatal neurology. We have been
stimulated in this work by such ﬁgures as Pasko Rakic
(Yale), Carla Shatz (Harvard), and Ivan Kostovic (Croatia).
Lessons learned
In my nearly half a century in neonatal neurology, I have
learned many lessons. Some of them have involved the
politics of academic medicine, and these lessons are hardly
worth recounting. However, a select few lessons related to
neonatal neurology per se are more worthy of discussion. I
will conﬁne myself to the ﬁve most prominent.
Lesson #1dexamination of the infant requires patience, a careful
eye, and minimal intrusion
I am often asked to illustrate how I perform a neuro-
logical examination of the infant. The illustration, I fear, has
disappointed many who expected that I performed a series
of secret, all-revealing maneuvers. My examination of the
infant is dominated by careful observation and very little of
the poking, prodding, scratching, head-dropping maneu-
vers described inmany classical writings. Most of my time is
spent watching the infant, with some gentle touches, to
assess level of consciousness, eye position and movement,
facial symmetry and movement, head position, asymmetry
of limb positions, onset of spontaneous movement, and so
forth. Surely, of course, evaluation of tone, and reﬂexes has a
role, but most of my examination is performed by watching
the infant carefully. It has been somewhat embarrassing for
me at times, to watch visitors or trainees watch me watch
the infant, when I felt that they expected to see much more.
What have I learned?
Stand there and look, don’t just do something.
Lesson #2dwe attribute most importance to what we see by
neuroimaging, although what we see often is not of most
importance
The most notable example driving home this lesson is our
changing concept over the years of the most important brain
lesion affecting the preterm infant. In the 1970s and early1980s, CT and ﬁrst-generation ultrasonography identiﬁed
IVH in 40%-50% of very low birth weight infants. Indeed, CT
and ultrasonography are excellent for detection of these
hemorrhagic lesions and their major complication, post-
hemorrhagic hydrocephalus. The efforts of my group focused
heavily on these areas at this time. However, later in the
1980s, with improvements in ultrasonographic instruments,
the ﬁndings of periventricular echodensities and subsequent
echolucencies made it clear that “cystic”white matter injury,
or periventricular leukomalacia (PVL), was common and in
fact correlated better with subsequent neurological deﬁcits
than did IVH. Into the 1990s, more careful assessment of
ultrasound scans revealed that PVL without subsequent
echolucencies, “noncystic” PVL, was more common than
realized and indeed could be the dominant pathology in very
low birth weight infants. With the advent of magnetic
resonance imaging (MRI) in the late 1990s to early 2000s, the
predominance of “noncystic” PVL and the relative infre-
quency of serious IVH and cystic PVL became clear. However,
from the turn of the century to the present, advanced MRI
(volumetric and diffusion-based methods) has provided ev-
idence for neuronal/axonal disease in preterm infants with
PVL. This work challenged the long-standing distinction that
preterm infants exhibit principally white matter disease and
term infants, gray matter disease. Most recently, advanced
human neuropathologic studies have delineated multiple
neuronal/axonal abnormalities in preterm infants with PVL,
and the concept of the “encephalopathy of prematurity,” a
disorder of both white and gray matter, has evolved.
What have I learned?
To fully understand the nature and spectrum of pathol-
ogy in preterm infants, we must return to the largely
neglected neuropathologic study of the human brain, but
now using advanced immunocytochemical and related
molecular methods.
Lesson #3dwe often forget about the infant when formulating
translational interventions
An important example underlying this lesson is the
preterm infant with PVL. Many experimental models of PVL
suggest therapeutic/prophylactic beneﬁt for such com-
pounds as antimicroglial agents (e.g., minocycline), excit-
atory amino acid antagonists (e.g., topiramate, memantine),
free radical scavengers (e.g., N-acetylcysteine, vitamins E/
K), and antiapoptotic agents (e.g., erythropoietin, insulin-
like growth factor-1). To translate these interventions to
the clinical arena, it is critical to determine their direct
relevance to the human premature brain. Recent advanced
neuropathologic studies of premature brain suggest that
many cellular and molecular events demonstrable in
experimental models appear to occur also in human PVL
and that several of the agents just observed, at least theo-
retically, could be useful. Yet, are they safe? Safety relates in
considerable part to the likely duration of therapy required.
How long should a preterm infant be treated to prevent
PVL? The answer to this key question is not entirely known.
Treatment with several of these agents for a day or two is
quite different, in terms of safety, than when the duration
must bemanyweeks. Indeed, considerable clinical evidence
suggests that the insults responsible for PVL (hypoxic-
J.J. Volpe / Pediatric Neurology 51 (2014) 753e757756ischemic or inﬂammatory or both) are chronic and cumu-
lative, perhaps occurring over many weeks. Safety concerns
concomitantly are greatly enhanced. Formulation of human
clinical trials must be preceded by careful animal studies
that involve long durations of therapy.
What have I learned?
In spite of personal involvement over many years in basic
and clinical research delineating pathogenetic mechanisms
in PVL and discovering potential preventative interventions,
too rapid a leap to the clinical arena cannot be justiﬁed. We
must use direct neuropathologic studies of the premature
brain to ensure relevance of experimental models to the
human lesion, and we must ensure that we will not harm
the infant by translational therapies, especially when
administered over relatively long periods.Lesson #4dwe forget that neonatal brain is vigorously developing
and that neonatal brain injury results not only in tissue loss but also
disturbances in subsequent brain development
The most notable example of this lesson is illustrated best
by the brain abnormalities occurring in the preterm infant.
Beginningabout40yearsago, conventionalneuroimaginghas
revealed a subsequent disturbance inmyelination in preterm
infants with PVL. The cellular basis for this disturbance was
not clearly revealeduntil the late 1990s andearly 2000swhen
advanced neuropathologic studies by us (led by Dr. Hannah
Kinney and Dr. Stephen Back) and others demonstrated that
the predominant oligodendroglial cell in the human prema-
ture white matter is an early differentiating, premyelinating
oligodendrocyte (pre-OL) and that this cell differentiates to
myelin-producing mature OLs largely after term. This rapidly
developing cell was demonstrated in experimentalmodels to
be vulnerable to injury by hypoxia ischemia and inﬂamma-
tion, the two key insults leading to human PVL. Advanced
human neuropathologic studies then demonstrated that
these rapidly developing cells in the premature brain acutely
were either lost or irreversibly injured with PVL. However,
more recent human immunocytochemical and molecular
studies demonstrate that there is later replenishment of pre-
OLs by proliferation of progenitors but a failure ofmaturation
of these cells. The result is a post-term deﬁcit of mature OLs
and the long-recognized hypomyelination. Thus, initial
“injurious” insults to rapidly differentiating cells were fol-
lowed by a failure of maturation.
Importantly, in parallel, advanced neuropathologic
studies, again in collaboration with Dr. Kinney, have been
delineating a remarkable array of disturbances in matura-
tion of rapidly developing white matter axons and key
neuronal structures, including cerebral cortex, subplate
neurons, and thalamus. The MRI correlates in the living
preterm infant are subsequent volumetric and microstruc-
tural deﬁcits in these structures.
What have I learned?
The ultimate brain abnormality in preterm infants is a
complex amalgam of primary destructive and secondary
developmental disturbances of both white and gray matter
structures. Advanced human neuropathologic studies are
the most reliable means to identify both categories of ab-
normality. Moreover, and perhaps even more importantly,this combination of primary and secondary disturbances
likely occurs with every neonatal destructive event, in both
term and preterm infants. Among term infants, however,
essentially no investigations have addressed the role of
secondary developmental disturbances in brain initiated by
the neonatal destructive events, whether the latter be
asphyxial hypoxic-ischemic injury or a variety of other en-
cephalopathies. Awareness of this general principle of
subsequent secondary brain developmental disturbances
consequent to primary injury in the neonatal period could
lead to striking new insights into the nature and complexity
of the later neuroanatomic defects and the bases for the
varied neurological disabilities subsequently encountered.
Moreover, because these later anatomical deﬁcits occur
over many weeks to months, a long window likely exists for
interventions, whether pharmacologic, behavioral, envi-
ronmental, nutritional, or cellular/genetic.
Lesson #5dwe think that we know it all
When I began my focus on the neurology of the newborn
over 40 years ago, neonatologists generally could not ﬁnd a
neurologist for consultation during the acute period of
neurological illness in one of their patients. The early 1970s
represented an era when child neurology was a specialty
principally focused on diagnosis and, often, on a somewhat
leisurely approach to diagnosis at that. My early ﬂedgling
years in the neonatal intensive care unit as a combined
neonatologist/neurologist taught me that for a neurologist
to be of value to the infant with neurological disease and to
the neonatal caregivers, a willingness to “put on your boots
and roll up your sleeves” during the acute period was crit-
ical. In the early 1990s, a former trainee in child and
neonatal neurology and then young faculty member in my
Department of Neurology at Boston Children’s Hospital,
Adre du Plessis, took up this challenge and shortly created a
remarkably active neurointensive care program, a nidus for
state-of-the-art clinical research, teaching, and neonatal
neurological care. Over the ensuing years it became clear
that to take neonatal neurology to the next level, combined
programs not only of neonatology and neonatal neurology
but also of neuropathology, neuroradiology and neurobi-
ology were needed. Over the past 30-40 years few such
programs have evolved in the United States and abroad.
Notable recent exceptions to this statement include the
superb programs led by Donna Ferriero (neurology), David
Rowitch (neonatology) and Jim Barkovich (neuroradiology)
at UCSF, and by Terrie Inder (neonatology), Jeff Neil
(neurology), and Robert McKinstry (neuroradiology) at
Washington University in St. Louis. The achievements of the
few exceptions have been stellar and have been critical in
moving our ﬁeld forward in more than simply incremental
ways. Of course, much work in programs that are not yet
multidimensional has been important also, in spite of the
difﬁculties.
What did I learn?
Brieﬂy stated, we need each other. “Turf battles” are a
waste of time and energy. Resources for such multifaceted
programs are not trivial to obtain, but combinations of
institutional, philanthropic, and external funds are obliga-
tory. However, even in the presence of such funds, in
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collaborative programs. Nevertheless, we do need each
other, and together remarkable accomplishments for our
ﬁeld and especially for our babies are possible.
A ﬁnal caveat
Except for the names of my earliest teachers and men-
tors, the trainees who have been unusually productive, and
colleagues worldwide who have been especially stimu-
lating to me, for fear of overlooking, I purposely have not
attempted to name all the many individuals who have
inﬂuenced me in clinical and research areas and with
whom I have had the privilege of working, i.e., neuropa-
thologists, neurologists, neonatologists, neurobiologists,
neuroradiologists, residents, fellows, and others. Col-
leagues and collaborators at Washington University in St.
Louis (1971-1990) and at Harvard Medical School (1990-
present) have particularly enriched my clinical andTo understand a science it is nresearch endeavors; without them very little could have
been accomplished. There are so many such individuals,
that if I attempted to name all of them, likely I would be
unsuccessful, and this presentation would be too ency-
clopedic. For the same reasons, I have not addressed many
ﬁelds so prominent in neonatal neurology and of great
interest to me, e.g., developmental/genetic disorders, sei-
zures, hemorrhagic diseases, hypoglycemia, kernicterus,
metabolic/degenerative disorders, neuromuscular diseases,
infectious processes, brain tumors, traumatic disorders; for
those areas I must shamelessly refer the reader to
Neurology of the Newborn, as well as to other sources.
Finally, I must particularly thank the more than 50
research trainees from neurology, neonatology, and
neurobiology and the countless number of child neurology
residents who have worked with and greatly stimulated
me over these past 40 plus years. Attempting to nurture
their young careers has been the ultimate joy of my aca-
demic life.ecessary to know its history.
Auguste Comte
